Founded in 2006, Windham is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical
Business Model:
Revenue: $8M
Employees: 11-50
Address: 1325 Avenue of the Americas
City: New York
State: NY
Zip: 10019
Country: US
Founded in 2006, Windham is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical technology (devices and diagnostics) and digital health (the intersection of biology, genomics, and information technology). Windham seeks to invest in and partner with companies that are commercializing game-changing technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors. For more information visit: www.windhamvp.com
Contact Phone:
+12127638525
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2014 | Welldoc | Series A | 20M |
1/2018 | NeuSpera Medical | Series B | 26M |
7/2021 | NeuSpera Medical | Series C | 65M |
10/2022 | SubjectWell | Series B | 35M |
6/2019 | andros | Series B | 14M |
9/2021 | Clever Care Health Plan Inc. | Series B | 71M |
3/2016 | Science Exchange | Series B | 25M |
12/2019 | ChromaCode | Series C | 0 |
6/2017 | Earlens | Series C | 0 |
10/2019 | Science Exchange | Debt Financing | - |
8/2018 | MC10 | Venture Round | 0 |
3/2021 | Upward Health | Venture Round | - |
10/2022 | Valera Health | Venture Round | 0 |
11/2021 | Valera Health | Venture Round | 0 |
2/2021 | Personal Genome Diagnostics | Series C | 0 |
6/2018 | Cureatr | Venture Round | 3M |
8/2019 | CVRx | Series G | 93M |
1/2018 | Personal Genome Diagnostics | Series B | 75M |
10/2018 | Nebula Genomics | Series A | 0 |
6/2015 | Cureatr | Series B | 0 |
4/2014 | Nuvaira | Series D | 42M |
12/2012 | MC10 | Series C | 10M |
1/2016 | GlySens | Series D | 20M |
5/2012 | Neotract | Series C | 37M |
4/2015 | Nuelle | Venture Round | 7.1M |
1/2021 | Delfi Diagnostics | Series A | 0 |
2/2019 | NeuSpera Medical | Series B | 12M |
1/2017 | Neotract | Venture Round | 12.8M |
7/2014 | HelpAround Medical | Convertible Note | 610k |
3/2023 | Clever Care Health Plan Inc. | Series C | 0 |
10/2014 | VytronUS | Series B | 31.6M |
4/2018 | Fore Biotherapeutics | Venture Round | 6M |
1/2016 | DOTS | Series A | 10M |
9/2020 | Willow | Series C | 0 |
6/2015 | Coravin | Series C | 13.6M |
1/2017 | Cartiva | Series E | 8.5M |
8/2011 | MC10 | Series B | 2.5M |
10/2015 | Personal Genome Diagnostics | Series A | 21.4M |
5/2015 | Cartiva | Series D | 8.5M |
9/2009 | Neotract | Series B | 28.1M |
9/2022 | Upward Health | Series B | - |
2/2021 | Valera Health | Venture Round | 0 |
9/2020 | ControlRad | Series C | 12.3M |
9/2014 | Ivantis | Series B | 25M |
1/2020 | HelpAround Medical | Series A | 6M |
2/2019 | Nuvaira | Equity | 79M |
10/2022 | Alto Neuroscience | Series B | 35M |
10/2019 | Science Exchange | Equity | 20M |
5/2021 | Alto Neuroscience | Series A | 0 |
1/2014 | Neotract | Venture Round | 50.6M |
6/2019 | SubjectWell | Series A | 10M |
10/2022 | Vergent Bioscience | Series B | 0 |
5/2015 | ClarVista Medical | Series B | 0 |
10/2018 | Earlens | Series D | 0 |
7/2022 | Delfi Diagnostics | Series B | 0 |
8/2019 | Delfi Diagnostics | Seed Round | 5.5M |
11/2010 | Transactis | Series B | 7M |
7/2022 | Delfi Diagnostics | Series B | 0 |
11/2021 | Valera Health | Venture Round | 0 |
9/2021 | Clever Care Health Plan Inc. | Series B | 0 |
7/2021 | NeuSpera Medical | Series C | 0 |
5/2021 | Alto Neuroscience | Series A | 0 |
3/2021 | Upward Health | Venture Round | - |
2/2021 | Personal Genome Diagnostics | Series C | 0 |
2/2021 | Valera Health | Venture Round | 0 |
1/2021 | Delfi Diagnostics | Series A | 0 |
9/2020 | Willow | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|